Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $48.2222.

Several analysts have weighed in on TYRA shares. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a research note on Friday. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. JonesTrading initiated coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, Wolfe Research started coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company.

Tyra Biosciences Stock Up 15.2%

TYRA stock opened at $28.65 on Monday. The stock has a market capitalization of $1.71 billion, a PE ratio of -11.94 and a beta of 0.73. Tyra Biosciences has a 52 week low of $11.70 and a 52 week high of $40.65. The firm has a 50 day moving average of $29.02 and a 200 day moving average of $32.03.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities research analysts expect that Tyra Biosciences will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. Walleye Capital LLC purchased a new stake in shares of Tyra Biosciences in the second quarter worth about $11,112,000. 5AM Venture Management LLC purchased a new position in Tyra Biosciences during the second quarter valued at approximately $32,875,778. Seven Fleet Capital Management LP lifted its holdings in Tyra Biosciences by 149.6% in the first quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company’s stock valued at $7,606,000 after acquiring an additional 119,025 shares during the period. Bank of America Corp DE lifted its holdings in Tyra Biosciences by 448.0% in the first quarter. Bank of America Corp DE now owns 209,922 shares of the company’s stock valued at $8,040,000 after acquiring an additional 171,612 shares during the period. Finally, Algert Global LLC boosted its position in Tyra Biosciences by 27.2% in the 2nd quarter. Algert Global LLC now owns 239,120 shares of the company’s stock worth $7,637,000 after purchasing an additional 51,110 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.